ArticleAlimentary pharmacology & therapeutics2019
Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease.
Article in Alimentary pharmacology & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Multi-Omics Biomarkers for Predicting Efficacy of Biologic and Small-Molecule Therapies in Adults With Inflammatory Bowel Disease: A Systematic Review.United European gastroenterology journal · 2025Pooled it
- Metabolism and response to stress gene signatures reveal ulcerative colitis heterogeneity and identify patients with increased response to therapy.Journal of Crohn's & colitis · 2025Trial
- BRD4 contributes to the cytokine-induced acquisition of an IL-13RA2-positive inflammatory fibroblast phenotype.Journal of Crohn's & colitis · 2026Article
- IL11+ fibroblasts are implicated in nonresponse to anti-TNF-α via fibrosis in inflammatory bowel disease.JCI insight · 2026Article
- Combining Cytokine-Related Biomarkers to Better Define Tumor Necrosis Factor-α Antagonist Response in Inflammatory Bowel Disease: An Observational Cohort Study.Clinical and translational gastroenterology · 2026Observational
- Genetic factors that predict response and failure of biologic therapy in inflammatory bowel disease.World journal of experimental medicine · 2025Review
- Aberrant expression of PYGB as a potential therapeutic target and its associations with immune cell infiltration in lung cancer.Frontiers in immunology · 2025Article
- Deciphering Microbial Composition in Patients with Inflammatory Bowel Disease: Implications for Therapeutic Response to Biologic Agents.Microorganisms · 2024Article
- Challenges in IBD Research 2024: Precision Medicine.Inflammatory bowel diseases · 2024Review
- Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease.International journal of molecular sciences · 2024Review
- Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions.eGastroenterology · 2024Review
- A novel role of prognostic nutritional index in predicting the effectiveness of infliximab in Crohn's disease.Annals of medicine · 2023Article
- Prediction of anti-TNF therapy failure in ulcerative colitis patients by ensemble machine learning: A prospective study.Heliyon · 2023Article
- Gut Microbiome and Metabonomic Profile Predict Early Remission to Anti-Integrin Therapy in Patients with Moderate to Severe Ulcerative Colitis.Microbiology spectrum · 2023Article
- Harnessing the Power of Precision Medicine and Novel Biomarkers to Treat Crohn's Disease.Journal of clinical medicine · 2023Review
- Targeted Assessment of Mucosal Immune Gene Expression Predicts Clinical Outcomes in Children with Ulcerative Colitis.Journal of Crohn's & colitis · 2022Article
- Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease.Genome medicine · 2022Article
- Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All.Journal of Crohn's & colitis · 2022Article
- Serum IL-13 Predicts Response to Golimumab in Bio-Naïve Ulcerative Colitis.Journal of clinical medicine · 2022Article
- Hyperactive neutrophil chemotaxis contributes to anti-tumor necrosis factor-α treatment resistance in inflammatory bowel disease.Journal of gastroenterology and hepatology · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundIleocolonic expression of IL13RA2 has been identified as a predictive marker for nonresponsiveness to infliximab (IFX) in patients with Crohn's disease (CD).
aimTo validate the IL13RA2 biomarker, study its anti-TNF specificity and get a better understanding of the underlying biology driving its expression.
methodsIL13RA2 mucosal expression was studied in a cohort of adalimumab and vedolizumab treated patients. To identify the upstream regulators of anti-TNF nonresponsiveness, weighted gene co-expression network analysis was applied on publicly available microarray data of IFX-treated patients. Selected serum proteins, including TNF, were measured prior to first IFX exposure and compared between healers and nonhealers.
resultsIncreased mucosal IL13RA2 expression prior to start of biological therapy was predictive for anti-TNF nonresponsiveness specifically (AUROC, area under the curve = 0.90, P < 0.001 in anti-TNF vs AUROC = 0.63, P = 0.30 in vedolizumab treated patients). In baseline biopsies, TNF-driven pathways were significantly enriched in future anti-TNF nonhealers (P = 5.0 × 10
conclusionsIncreased mucosal IL13RA2 expression is associated with an increased mucosal TNF burden in CD patients. In view of its specificity for prediction of anti-TNF therapy resistance, mucosal IL13RA2 expression is a potential biomarker for therapy selection and/or for the need of increased anti-TNF drug dosing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.